AbbVie faces hepatitis C patent challenge in India

26-07-2018

AbbVie faces hepatitis C patent challenge in India

Hailshadow / iStockphoto.com

In India, a non-profit organisation and an advocacy group have united to take on a patent covering pibrentasvir, part of the drug combination that forms AbbVie’s hepatitis C product Mavyret.


I-MAK, Delhi Network of Positive People, Indian Patent Office, AbbVie, hepatitis C, Mavyret, generics, obviousness,

LSIPR